Written answers

Tuesday, 16 April 2013

Department of Health

Medicinal Products Supply

Photo of Finian McGrathFinian McGrath (Dublin North Central, Independent)
Link to this: Individually | In context | Oireachtas source

To ask the Minister for Health if he will support lung fibrosis patients here as a matter of urgency (details supplied). [17403/13]

Photo of Terence FlanaganTerence Flanagan (Dublin North East, Fine Gael)
Link to this: Individually | In context | Oireachtas source

To ask the Minister for Health his views regarding the refusal of the National Centre for Pharmacoeconomics, NCPE, to recommend funding for Pirfenidone for patients with lung fibrosis (details supplied); and if he will make a statement on the matter. [17424/13]

Photo of Alex WhiteAlex White (Dublin South, Labour)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 1316 and 1317 together.

Following a pharmacoeconomic evaluation of pirfenidone (Esbriet), the National Centre for Pharmacoeconomics concluded that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate idiopathic pulmonary fibrosis. The HSE is currently in negotiations with the manufacturers of pirfenidone (Esbriet) and therefore it would not be appropriate to comment further while these negotiations are ongoing. The application to the HSE for the reimbursement of this product under the Community Drugs Schemes is being considered in line with the agreed procedures and timescales for the assessment of new medicines as per the 2012 agreement between the Irish Pharmaceutical Healthcare Association, the HSE and the Department of Health.

Comments

No comments

Log in or join to post a public comment.